Crisdesalazine
Crisdesalazine ( ; developmental code name AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor and free radical scavenger which is under development for the treatment of Alzheimer's disease, amyotrophic lateral…
≈ 1 min read
Crisdesalazine. encyclopegia.org, snapshot enwiki-001370137270. /a/crisdesalazine
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Crisdesalazine ( ; developmental code name AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor and free radical scavenger which is under development for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), depressive disorders, Parkinson's disease, and spinal muscular atrophy. It was also under development for the treatment of arthritis, diabetes, pain, and pancreatitis, but development for these indications was discontinued.
Crisdesalazine is also approved under the brand name GedaCure for treatment of dogs with canine cognitive dysfunction.
See also
List of investigational antidepressants List of investigational Parkinson's disease drugs Selegiline § Veterinary use
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370137270 under CC BY-SA 4.0; modifications have been made.